Using brain imaging to improve treatment for PTSD with TMS

Targeting the Default Mode Network: A TMS-fMRI Study

Not applicable Interventional Palo Alto Veterans Institute for Research · NCT05646732

This study is testing if brain scans can help improve a treatment called rTMS for people with PTSD by finding out how it affects their brain.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment30 (estimated)
Ages18 Years to 55 Years
SexAll
SponsorPalo Alto Veterans Institute for Research Academic / other
Locations1 site (Palo Alto, California)
Trial IDNCT05646732 on ClinicalTrials.gov

What this trial studies

This study investigates the effects of repetitive transcranial magnetic stimulation (rTMS) on the default mode network (DMN) in patients with post-traumatic stress disorder (PTSD). By utilizing functional magnetic resonance imaging (fMRI), researchers aim to identify brain regions that change in response to rTMS, potentially leading to a personalized treatment approach for PTSD. Participants will undergo psychological assessments, MRI scans, and two TMS-fMRI sessions, with a total participation time of five to six hours. The study is conducted at VA Palo Alto and Stanford University.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 to 55 with a primary diagnosis of PTSD who can safely undergo MRI and TMS procedures.

Not a fit: Patients with significant dementia or those unable to safely undergo MRI or TMS will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to more effective, personalized treatments for PTSD, improving patient outcomes.

How similar studies have performed: While there have been studies targeting the DMN in other conditions, this specific approach using rTMS in PTSD is novel and has not been extensively tested.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Between 18 and 55 years of age
* Ability to maintain a Motor Threshold (MT) with single pulse TMS
* Ability to safely and comfortably undergo an MRI and TMS
* Able to read, verbalize, understand, and voluntarily sign the Informed Consent Form prior to participating in any study-specific procedures or assessments.
* PTSD diagnosis according to the DSM 5, as determined by the Clinician administered PTSD scale (CAPS-5) criteria.
* Commitment to maintaining a stable medication regimen between the two fMRI sessions

Exclusion Criteria:

* Inability to safely and comfortably undergo an MRI. MRI safety will be determined by the center where MRI's are collected.
* Inability to safely and comfortably undergo TMS. TMS exclusions include any history or condition that puts patients at risk.
* Significant dementia as determined by the Montreal Cognitive Assessments (MoCA)
* Common comorbid disorders of Veterans are allowed, but PTSD must be a primary diagnosis causing significant impairment that could not be accounted for by another diagnosis. Medical or mental health conditions that interact with or confound interpretation of PTSD symptoms and anxiety would be exclusionary.
* Being in urgent need of care that would make participation impossible
* Currently taking medications that increase the risk of seizure or influence hemodynamic response
* Presence of any other condition that has the potential to prevent study completion and/or have a confounding effect on the interpretation of results.

Where this trial is running

Palo Alto, California

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Post Traumatic Stress DisorderPTSDTranscranial Magnetic StimulationTMSMagnetic Resonance ImagingMRIfMRITMS-fMRI
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.